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ABSTRACT 
     
 
Nucleosides and nucleoside analogues exhibit a broad spectrum of biological activities 
including antiviral, anticancer, antibacterial and antiparasitic activities, which generally 
result from their ability to inhibit specific enzymes.  Nucleoside analogues can interact 
with cellular enzymes involved in the biosynthesis or degradation of RNA (ribonucleic 
acid) and/or DNA (deoxyribonucleic acid) or with specific viral enzymes to result in their 
biological activities and therapeutic effects.  In addition, another possible target is their 
incorporation into DNA/RNA which could affect replication and transcription.  They 
have been beneficial to the development of new pharmaceuticals.  Squaric acid and its 
derivatives have been successfully used as a bioisosteric group in various biomedicinal 
areas.  The aim of this research proposal was to apply squaric acid analogues to the 
design and synthesis of novel nucleoside analogues.   
Three squaric acid-based new nucleoside analogues were made starting from dimethyl 
squarate.  The compounds were 4-amino-3-[((1R,3S)-3-hydroxymethyl-4-cyclopentene)-
1-amino]-3-cyclobutene-1,2-dione, 4-methoxy-3-[((1R,3S)-3-hydroxymethyl-4-cyclopen 
tene)-1-amine]-3-cyclobutene-1,2-dione, and 4-hydroxy-3-[((1R,3S)-3-hydroxymethyl-4-
cyclopentene)-1-amine]-3-cyclobutene-1,2-dionate, sodium salt.  A key step in their 
synthesis was the reaction of (1R, 4S)-(-)-4-(hydroxymethyl)cyclopent-2-en-1-ylamine 
with 4-amino-3-methoxy-3-cyclobutene-1,2-dione, or 3,4-dimethoxy-3-cyclobutene-1,2-
dione, followed by hydrolysis to give the above compounds.   
 iii
They were sent to the Developmental Therapeutics Program (DTP) of the National 
Cancer Institute (NCI, USA) to screen and test in vitro for their potential anticancer 
activity in cellular assays.  Little to modest antitumour activity was detected for these 
compounds.  Meanwhile, their cytotocity to HeLa cells was investigated as well.  
However, no significant effect was observed by these three compounds.  Also, these 
compounds were sent out to the National Institute of Allergy and Infectious Diseases 
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1.1 Bioisosterism in drug design 
Drug design is of critical importance in human health care.  It is a process whereby the 
design and synthesis of a compound are undertaken and the biological and physical 
properties of a lead compound are studied [1].  A lead compound should be well 
understood as to its desired pharmacological activity and also as to its undesirable side 
effects, metabolic pathways, and structural factors related to its physicochemical 
characteristics which can limit the compound’s bioavailability [2].  Bioisosterism is a 
method used in medicinal chemistry for the rational modification of a lead compound in 
order to improve its pharmacological activity, reduce its adverse effects or even optimize 
the biological activity and the pharmacokinetics that the lead compound might have.  
Such modifications may enhance the safety and therapeutic efficacy of the compound 
under investigation [3]. 
 
1.1.1 A primer on bioisosterism 
    The antecedent of bioisosterism is isosterism, which was first reported by Langmuir in 
1919 regarding the similarities of various physicochemical properties of atoms, groups, 
radicals, and molecules [4].  Some of these groups are listed in Table 1 [3]. 
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In 1925, Grimm further broadened this concept of isosteres with his Hydride 
Displacement Law (From the left to the right in Table 2) [2].  This law states that one 
hydrogen atom (H) with a pair of electrons (i.e. hydride) is added after another atom and 
gives a new isoelectronic pseudoatom with properties with the same physical 
characteristics of the elements and groups in the vertical columns behind the original 
atom [5].  
 






    A further extension of the concept of pseudoatoms came about in 1932 by Hans 
Erlenmeyer.  He redefined isosteres as atoms, ions, and molecules with the same number 
of electrons at the valence level [3] and created a concept of electronically equivalent 
rings, later broadened to the term ring bioisosterism [2]. 
During the early 1950s, Harris L. Friedman foresaw the application of the concept of 
isosterism to the design of bioactive molecules [6].  He coined the term bioisosterism to 
include all atoms and molecules which fit the broadest definition of isosteres and exercise 
their biological activity, no matter whether they act as agonists or antagonists (an agonist 
being a compound that interacts with a receptor eliciting a response and an antagonist one 
that prevents the action of agonists at the receptor) [7].  However, Thornber found that 
the term bioisosterism introduced by Friedman was to describe the phenomenon in which 
structurally related substances have similar or antagonistic biological properties [5].  So a 
loose flexible term for bioisosteres was defined as: “Bioisosteres are subunits or groups 
or molecules which possess physicochemical properties of similar biological effects” [5].  
In 1991, this definition was broadened by Burger as “Bioisosteres are compounds or 
groups that possess near-equal molecular shapes and volumes, approximately the same 
distribution of electrons, and which exhibit similar physical properties such as 
hydrophobicity.  Bioisosteric compounds affect the same biochemically associated 
systems as agonists or antagonists and thereby produce biological properties that are 





1.1.2 Some important bioisosteric groups 
Bioisosteres have been classified as either classical or non-classical.  Classic 
bioisosteres have been divided into: (A) monovalent atoms or groups; (B) divalent atoms 
or groups; (C) trivalent atoms or groups; (D) tetravalent atoms; and (E) ring equivalents 
[3].   They are successfully used in the structural design of new drugs.  For example, ring 
bioisosterism is one of the most useful approaches in the drug design of different 
therapeutic classes [7].  Binder and coworkers had successfully explored new non-steroid 
anti-inflammatory drugs (NSAIDs) of the oxican group by application of ring 
bioisosterism (Scheme 1.1) [2].  Piroxicam is a prototype NSAID belonging to the 
oxicam group.  The benzothiazinic nucleus of piroxicam was replaced by the 
thienothiazinic moiety to synthesize tenoxicam. Isoxicam and meloxicam possess a 5-
methylisoxazole ring and 5-methyl-2-thiazolyl ring respectively, as an equivalent of the 
pyridine ring of piroxicam and tenoxicam [8].  So the ring bioisosteres of the 
benzothiazinic nucleus may have the same or similar pharmacotherapeutic profiles as 
piroxicam and tenoxicam, while other bioisosteres at the pyridine ring may have the same 



















































isoxicam meloxicam  
Scheme 1.1 
 
Non-classic bioisosteres are those groups which practically do not fit the steric and 
electronic definitions of classical isosteres.  Moreover, they do not have the same number 
of atoms as the substituent or moiety. Non-classic bioisosteres can be divided into groups: 
(A) cyclic vs noncyclic; (B) functional groups; (C) retroisosterism [2].  They have a 
significant predominance in drug design because of their utility in distinct therapeutic 
categories such as selective receptor antagonist or agonist drugs, enzyme inhibitors or 
anti-metabolites [3].  Consider the bioisosterism of functional groups as an example.   
Numerous functional groups are known for their bioisosteric replacement of the 
carboxylate group such as sulfonamide [3], tetrazole [2], phosphonate [7], and sulfonate 
[7]  groups (Scheme 1.2).  The similarities of these bioisosteres are based on electronic 





















































1.2 Squaric acid analogues as bioisosteric groups 
 
Squaric acid (3,4-dihydroxy-3-cyclobutene-1,2-dione) is an intriguing multi-functional 
organic molecule which has a cyclobutenyl ring system [9].  It has 2π electrons in its 
completely deprotonated form and a negative charge on each of the carbonyl oxygen 
atoms in its resonance form (Figure 1) [10, 11].   It has been suggested that this resonance 
structure serves as a good electrostatic mimic for negatively charged groups such as the 
carboxylate group and phosphate group [12].  Furthermore, reaction of squaric acid 1 
with alcohols produces esters 2.  This reaction occurs readily in the presence of an acid 
catalyst like the usual esterification of carboxylic acids.  Replacing the squaric acid esters 
2 by amines gives the corresponding diamides 3 or monoamide monoesters 4 (Figure 1).  
These have been applied to enhance the biological activity of several drugs and to 
functionalize organic molecules [10].  As a result, derivatives of squaric acid have 

















































Figure 1: Structures of squaric acid (1), squarates (2), squaryldiamides (3) and squaric 
monoamide monoesters (4); and resonance structures of squaric acid showing the 
electrostatic similarity to phosphate group and carboxylate group [10, 13]. 
 
1.2.1 Literature review of biomedical applications of squaric acid analogues 
Since squaric acid was first synthesized by Cohen et al. in 1959 [14], a number of  
derivatives have been generated and some of their properties have been studied in 
different areas in recent years.  A number of pharmaceutical applications of squaric acid 
diesters are known.  For instance, the di-n-butylester of squaric acid is a potent allergen 
and has been used in the treatment of alopecia areata, a non scarring form of hair loss, 
and in the immunotherapy of warts in children [15-18].  
A number of other squaric acid amide-based pharmaceutically active compounds have 
been studied.  For example, squaric acid derivatives have been used to mimic 
carboxylates or the α-aminocarboxylic acid unit for various receptor molecules by several 
investigators.  Kinney and coworkers replaced the entire α-amino carboxylic acid in 
various N-methyl-D-aspartic acid (NMDA) antagonists with a squaric acid derivative 
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(3,4-diamino-3-cyclobutene-1,2-dione) (Scheme 1.3) [19].  At physiological pH, the α-
amino carboxylic acid group is present as its zwitterion.  The 3,4-diamino-3-cyclobutene-
1,2-dione moiety contains a dipole possessing a partial negative charge on the carbonyls 
and a partial positive charge on the nitrogen atoms (Scheme 1.3).  For these stated 
reasons, Kinney chose the 3,4-diamino-3-cyclobutene-1,2-dione as a possible electronic 
mimic of the α-amino carboxylic acid to improve bioavailability and brain penetration of 




































As shown in Scheme 1.4, the α-amino carboxylic acid of compound 5 (glutamic acid) 
was replaced by 3,4-diamino-3-cyclobutene-1,2-dione to produce compound 6 [19].  
Examining the functional activities of compound 5 and 6 showed that compound 6 was a 
 9
weak functional NMDA antagonist relative to compound 5.  However, optimizing 
NMDA receptor potency of several phosphonic acid derivatives including compounds 7 






























Benny and co-workers [20] also used the 3,4-diamino-3-cyclobutene-1,2-dione group 
to substitute the α-amino carboxylic acid unit of 2-amino-3-(5-carboxy-3-ethoxy-4-
isoxazolyl)propionic acid 9 (Scheme 1.5).  The receptor binding of both compounds was 
studied using rat brain membranes.  Compound 9 is a potent inhibitor of [3H]AMPA (2-
amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid) receptor binding and showed 
agonist potency, while compound 10 was completely devoid of an effect on AMPA 























9 10  
Scheme 1.5 
     
The 3,4-diamino-3-cyclobutene-1,2-dione group has been also recognized as an 
isostere for functional groups, such as cyanoguanidine.  In the quest for new selective 
agonists of potassium channels, Butera and coworkers carried out modifications in the 
structure of anti-hypertensive lead compound pinacidil 11 (Scheme 1.6). They described 
the replacement of the N-cyanoguanidine template, present in pinacidil, with a 1,2-
diaminocyclobutene-3,4-dione moiety which afforded a novel series of potent bladder-
selective agonists of the KATP channel 12 and 13, as a novel drug candidate to treat urge 






























IC50 =0.63 X 10-6M
11 12
IC50 =1.3 X 10-6M
IC50 =0.09 X 10-6M
13
ED50 = 0.13 mg/kg (urinary incontinence)  
Scheme 1.6 
 
    Shinada replaced the phenol group of tyrosine within philanthotoxin (PhTX) and the 
amide group of glutamine within nephilatoxin-8 (NPTX-8) with squaric acid derivatives 
as shown in Scheme 1.7 [9].  The paralytic activity was examined for PhTX-343, NPTX-
8 and analogues 14 and 15.  The paralytic activity of compound 14 (R=OH or NH2) was 
10-100-fold less potent than that of PhTX-343.  On the other hand, the paralytic activity 
of compound 15 (R=OH or NH2) showed more potent paralytic activity than that of 
natural NPTX-8, even much more potent than those of PhTX-343.  Among them, the 
glutamine-type 15 (R=NH2) was found to be the most potent analog.  These compounds 
































































R= OH or NH2




    Derivatives of squaric acid have also been used to mimic the phosphate group in 
phosphotyrosine residues, and that these compounds can be used to design effective 
inhibitors of protein tyrosine phosphatases [11].  Sekine and co-workers have used a 
diamide of squaric acid to replace a phosphate diester linkage in an oligodeoxynucleotide 
16 (Scheme 1.8) [10].  The modified oligodeoxynucleotide 17 exhibited properties such 
as increased binding affinity for the target nucleic acid, a resistance to degradation by 



































     Beaulieu and co-workers replaced phosphate in a peptide-based ligand 18 for an SH2 
domain with squaric acid (Scheme 1.9) [23].  Unfortunately, the resultant compound 19 






























18 19  
Scheme 1.9 
 
    Recently, Chi-Wan Lee and co-workers discovered a novel peptidomimetic containing 
the squaryldiamide moiety as a new potential bioisosteric group for guanidine that binds 
transactivation responsive (TAR) RNA with high affinity (Scheme 1.10) [24].  
Compound 20 (inhibitor TR87) showed potent, sustained anti-HIV-1 activity that did not 
significantly affect cell viability in single-round replication assays.  The squaryldiamide 
derivative 21 was tested as a transactivator of transcription (Tat)-TAR inhibitor and was 
able to bind TAR RNA with high affinity.  In summary, the squaryldiamide could be 
used as a potential bioisostere of unsubstituted guanidine in peptidomimetics.  It was 
easily incorporated into a carbonate monomer which could then be coupled to produce 
































1.2.2 Previous work in our laboratory 
     Dr. P. Chan and co-workers in the Honek laboratory have used derivatives of squaric 
acid to substitute the carboxylate group to synthesize several novel N-
(hydroxydioxocyclobutenyl)-containing analogues of γ-amino-butyric acid and L-
glutamate [13].  Glutamate is an excitatory amino acid (EAA), which is a critical 
neurotransmitter in the central nervous system (CNS) [25].  The EAA neurotransmitter 
effects are mediated by three heterogeneous classes of ionotropic receptors named 
NMDA, AMPA, and kainic acid receptors and a number of subtypes of metabotropic 
receptors [26].  The subtypes of these receptors have been associated with certain 
neurologic and psychiatric diseases and have been suggested to be potential targets for 
the treatment of such diseases. 
     The three N-(hydroxydioxocyclobutenyl)-containing analogues 22, 23, and 24 (Figure 
2) were successfully synthesized by suitable protection of the diamine or diamino acid 
followed by reaction with diethyl squarate.  These analogues were screened as displacers 
in several receptor binding assays.   The diaminopropane analogue 23 showed poor 
affinity for various binding sites. The diaminoethane analogue 22 exhibited little affinity 
to GABAA and GABAB (GABA: γ-aminobutyric acid) binding sites.  In contrast, the 
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22 23 24 Quisqualate  
Figure 2:  The structure of three N-(hydroxydioxocyclobutenyl)-containing analogues 
and Quisqualate [13] 
  
Moreover, pharmacological actions and quisqualate (Figure 2) sensitization of neurons 
(QUIS-effect) by these three compounds 22, 23, and 24 were studied [13].  For 
pharmacological information, the compounds were examined for agonist potency for 
CA1 pyramidal neurons in a rat hippocampal slice preparation.  The results were that 
compounds 22 and 23 showed little activity in this assay, while compound 24 rivaled 
AMPA as one of the most potent agonists for depolarizing pyramidal neurons in media in 
which kainate/AMPA receptors were active but NMDA receptors were inhibited.  It was 
less potent for depolarizing pyramidal neurons in another media in which kainate/AMPA 
receptors were inhibited but NMDA receptors were active.  For the QUIS-effect, 
compounds 22, 23, and 24 did not induce sensitization of CA1 pyramidal neurons and did 




1.3 Nucleoside analogues 
Nucleosides and nucleotides are of fundamental importance for all living systems, such 
as structural modules of nucleic acids, cofactors, and messenger substances [27, 28]. 
Therefore, it is not surprising that nucleoside analogues have attracted considerable 
attention, mainly as antitumor, antiviral, antimicrobial [29], and immunosuppressive [30] 
agents in pharmacology. 
While certain nucleoside analogues are incorporated into nucleic acids as chain 
terminators, thereby interrupting the replication of cancer cells or a virus, others are 
designed to block certain enzymes necessary for cancer or viral reproduction.  Numerous 
modifications to heterocyclic nucleobase moieties as well as the sugar ring of the 
nucleosides have been applied for many years to increase their chemotherapeutic 
activities [31].  These studies have resulted in the development of many clinically useful 
drugs.   
 
1.3.1 Furanose-derived nucleoside analogues 
The base moiety of nucleosides has been replaced by five-membered heterocycles and 
these nucleosides exhibit a wide range of biological activities. Ribavirin (1-β-D-
ribofuranosyl-1,2,4-triazole-3-carboxamide, Figure 3) was the first synthetic nucleoside 
exhibiting a broad spectrum of antiviral activities against many RNA and DNA viruses 
[32].  There are many other nucleoside analogues of certain five-membered heterocycles, 
such as tiazofurin, bredinin, pyrazomycin, and pyrrole dicarboxamide (Figure 3).  These 
compounds are structurally similar to 5-amino-1-β-D-ribofuranosylimidazole-4-
carboxamide  (AICAR), which is a key intermediate in purine nucleotide biosynthesis 
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[33].  Thus, all of these nucleosides are potent inhibitors of inosine 5’-monophosphate 
(IMP) dehydrogenase.  The latter is one of the key rate-controlling enzymes for de novo 
guanine nucleotide biosynthesis and has been considered as a target enzyme for 
















































Pyrazomycin Pyrrole dicarboxamide AICAR  
Figure 3:  Nucleoside analogues containing certain five-membered heterocycles 
 
 Few studies have been done for pyrimidine-modified nucleosides, but these 
compounds have exhibited anticancer, antiviral and antibacterial activities.  For example, 
5-azacytidine (4-amino-1-β-D-ribofuranosyl-1,3,5-s-triazin-2-one, Figure 4) inhibits 
Gram-negative bacteria and is active against T-4 lymphomas and L-1210 leukaemia.  It 
has been used clinically in the treatment of acute leukemia [28].  The compounds 6-
azacytidine and 3-deazacytidine (Figure 4) have been prepared and also show anticancer 























5-Azacytidine 6-azacytidine 3-deazacytidine  
Figure 4: Some pyrimidine-modified nucleosides 
 
 A wide range of purine-modified nucleosides have been prepared and their biological 
activities have been examined.  Modifications of adenosine in the heterocyclic base 
moiety have led to many other biologically active molecules.  Tubercidin (Figure 5), the 
naturally occurring pyrrolo[2,3-d]pyrimidine analogue of adenosine, exhibits significant 
antineoplastic and antiviral properties [36].  The compound 2-azaadenosine (Figure 5) 
exhibits modest in vivo activity against L1210 cells [37].  The analogue 1-
deazaadenosine (Figure 5) has been used as an inhibitor of blood platelet aggregation and 
adenosine deaminase and shows potential antitumour activity [38, 39].  The compound 3-
deazaadenosine (Figure 5) acts as an alternate substrate competing with adenosine and 3-
deazaguanine (Figure 5) exhibits potential cytotoxic activity in vitro against a variety of 
tumor cells, such as L1210, HeLa, and human KB cells [40, 41].  In 2005, nelarabine 
(Figure 5) was approved by the US Food and Drug Administration (FDA) for oncology 
indication.  It is a prodrug of the antimetabolite 9-beta-D-Arabinofuranosylguanine (ara-























































Figure 5:  Some purine-modified nucleosides 
 
 
1.3.2 Carbocyclic nucleoside analogues 
     Due to their interesting biological activity,  carbocyclic nucleoside analogues (CANs) 
have also received much attention in recent years.  CANs, which have no conventional 
glycoside linkage between the base and the carbocycle replacing the sugar of true 
nucleosides, have an attractive in vivo stability advantage over the 2’,3’-
dideoxynucleosides, as well as being more lipophilic and hence potentially more readily 
absorbed because of the replacement of the endocyclic oxygen by a methylene group [27]. 
    The first member of this class was the carbocyclic analogue of adenosine described by 
Shealy in 1966 [43],  and the interest was spurred by the discovery of the antibiotic and 
antitumoural activities of the natural products aristeromycin [44] and neplanocin A [45] 
(Figure 6).  Since then, a large number of synthetic CANs have been prepared and tested 
[46]. Some of them were discovered with important therapeutic properties.  For example, 
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3-deazaristeromycin, an analogue of aristeromycin (Figure 6), shows interesting antiviral 
activities [47].   
Prominent synthetic CANs with anti- human immunodeficiency virus (HIV) activity 
are the 2’,3’-unsaturated compounds, such as 2’,3’-didehydro-2’,3-dideoxyguanosine 
(carbovir) [48], amino-carbovir and abacavir (Ziagen) (Figure 6).  The latter has better 
oral bioavailability and better penetration into the central nervous system than the other 
two and is currently being used in combination with other antiretroviral drugs to treat 
HIV infection in adults [49-52].  



















































1.4 Statement of goal 
     There are two fundamental approaches for the construction of nucleoside analogues: 1) 
convergent attachment of an intact sugar or carbocyclic ring with an appropriately 
functionalized heterocyclic base by substitution and 2) convergent attachment of an intact 
heterocyclic base with an appropriately functionalized sugar or carbocyclic ring by 
substitution.  We proposed to try both approaches to synthesize some novel nucleoside 








































Figure 7: The target compounds of nucleoside analogues to be synthesized 
 
Even though some carbocyclic nucleoside analogues are already in clinical use, this 
class of compounds still possesses a huge and largely unexploited potential for the 
development of new pharmaceuticals.  Nucleoside analogues with a four-membered 
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heterocyclic as the base moiety have not yet been studied.  So we proposed to use the 
carbocyclic ring as the sugar part of the nucleosides and to substitute the heterocyclic 
base by squarate analogues to synthesize novel types of carbocyclic nucleoside analogues.   
After synthesizing all the target compounds, we screened and tested their potential 






















DESIGN AND SYNTHESIS OF NUCLEOSIDE ANALOGUES 
 
2.1 Molecular modeling 
Molecular modeling is a theoretical method and computational technique to model or 
mimic the behaviour of molecules [53].  We used the program Spartan for Windows’ 06 
to show several potential alignments of N-methyldiaminosquarate with several nucleic 
acid bases (Figure 8).  From Figure 8, we can see that there is greater atomic overlap of 
N-methyldiamino squarate with 9-methyladenine and 9-methylguanine than with 1-
methylcytosine and 1-methyluracil.  This might indicate that the structure of squaramide 
could resemble adenine or guanine.  So it is of significant interest to utilize the 
monoamino squarate group as a base and modify the saccharide portion for nucleoside 
analogues to exploit the nucleoside platform as a source for new cellular probes and 





























9-Methylguanine A 9-Methylguanine B 
1-Methyluracil 
Figure 8: Alignments of N-methyldiamino squarate (in red) with several nucleic acid 
bases such as 9-methyladenine, 9-methylguanine and 1-methyluracil. 
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2.2 Synthesis of starting materials 
2.2.1 Synthesis of 3,4-dimethoxy-3-cyclobutene-1,2-dione (32) 
  The whole synthesis begins with the commercially available 3,4-dihydroxy-3-
cyclobutene-1,2-dione 31 (squaric acid) (Scheme 2.1), which is converted to its dimethyl 
ester 32 by refluxing a methanol solution of squaric acid in the presence of  excessive 
trimethyl orthoformate [54].  The result was the formation of the dimethyl ester on a 
multigram scale in 89% yield.  This route is convenient, safe and inexpensive for the 

















2.2.2 Synthesis of 4-amino-3-methoxy-3-cyclobutene-1,2-dione (33) 
Dimethyl squarate 32 was treated with ammonia gas to replace one of the methoxyl 
groups by an amino group [55] (Scheme 2.2).  The product 33 is a monoamino compound, 
which is quite insoluble in ether (0.02%) [55].  Therefore treatment of compound 32 in 
dry ether with ammonia gas led to precipitation of monoamino compound 33 which 
















2.2.3 Synthesis of 3, 4-diamino-3-cyclobutene-1,2-dione (34) 
The ammonolysis in the previous reaction also provided the diamino compound 34 in 
low yield.  In order to improve the yield, the solvent methanol instead of ether was used 
in this experiment, in which the monoamino compound 33 is soluble allowing for further 





















2.3 Synthesis of 4-amino-3-[(β-D-ribofuranosyl)-β-1-amino]-3- 
cyclobutene-1,2-dione (25) 
In the literature, the reaction of the 2,3-O-isopropylidene-β-D-ribofuranosylamine 35 
with the ethoxy-carbamate 36 in the presence of sodium methoxide in methanol gave the 
5-cyanoisopropylideneuridine 37, which subsequently reacted with trifluoroacetic acid 







































So in this study, we took product 33 at hand and reacted with commercially available 
2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate salt 35 in refluxing 
methanol or 1,4-dioxane (Scheme 2.5).  The second methoxyl group of squarate is known 
to be active towards amines under basic conditions [57], thus N,N-diisopropylethylamine 
was used as a base to adjust the ionization state of the mixture.  The mixture was stirred 
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at 68 °C-70 °C for 2 days to afford 4-amino-3-[(2,3-O-isopropylidene-β-D-



































Mass spectrometric analysis from this reaction was in agreement with the expected 
product mass characteristics (Calcd. For C12H16O6N2 (M + H+): 285.1086. Found 
285.1048) (Figure 9).  However, the yield was found to be low and there were a number 
of side products in the mixture based on observation of the thin layer chromatography 
(TLC) which was found to be complex and many spots had similar retention factor (Rf) 
values.  It was extremely difficult to obtain the pure product 39 by flash chromatography. 
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Figure 9: Mass spectrum (ESI+) for compound 39 
 
We assumed that the reaction time was not long enough. So we tried the reaction 
stirring for a longer time, 3 days and 7 days. But they were still the same as presented. 
Another possibility was that the base N,N-diisopropylethylamine was not strong enough.  
So we tried the base sodium methoxide (Scheme 2.5). The yield was also very low and it 
was difficult to purify the products.   
There are some possible reasons why the mixture was complex: (1) The monoester 
monoamino squarate 33 may react by itself to make a diamino disquarate (C8H2O4N2, 
Calcd. for (M + H+) 190.0093. Found 190.0430 in the mass spectrum as shown in Figure 
9). (2) The ribosylamine was unstable which might allow it to react with the solvent 
methanol or the hydroxyl group of the ribosylamine reacted with the monoamino squarate 
33. (3) The 2,3-O-isopropylidene group could be removed to uncover two hydroxyl 
groups and then these might have reacted with monoester monoamino squarate 33. The 
complex mixtures of products and lack of sufficient material led us to abandon our 
attempts to prepare the product 4-amino-3-[(β-D-ribofuranosyl)-β-1-amino]-3-
cyclobutene-1,2-dione 25. 
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2.4 Synthesis of 2-(β-D-ribofuranosyl)-3H-2,4-diazabicyclo[3,2,0] 
nona-1,3-diene (26) 
Triethyl orthoformate has been used in the formation of heterocyclic systems (Scheme 
2.6) [58].  We attempted to undertake similar reactions for compound 39 by attempting a 
ring closure reaction with triethyl orthoformate in the presence of hydrochloric acid in a 
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Unfortunately, we could not get the pure protected compound 39 to generate the 
product 26.  The yield of impure compound 39 was low as well.  So we collected the 
impure compound 39 several times and tried to generate the product 26 as presented 
above.  However, we did not obtain the compound 26 under these conditions based on the 
mass spectrum.  No more impure compound 39 was available to investigate this reaction.  
So we tried to model the ring closure of diamino squarate first (Scheme 2.7), but no 
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reaction occurred at all.  It may be because the diamide 34 is highly insoluble and 
presumably strongly hydrogen bonded.  Another factor in the lack of success in this 
reaction might be the presence of increased ring strain in the product, which would be a 
five membered ring fused to a four membered ring, versus, for example adenine, a five 
membered ring fused to a six membered ring system.  Molecular modeling of the product 
expected from reaction of 34 with triethyl orthoformate (Scheme 2.7) at the RHF/6-31* 
level using Spartan ’06 software indicates the product has a N-C-N bond angle of 114.56 
degrees whereas the bond angle for formamidine itself (HC(=N)NH2) is approximately 
125.3 degrees. It may be that this bond angle difference results in a higher energy for the 
squaric acid bicyclic base therefore making it energetically more difficult to close the 
ring.  A decrease in the reactivity of the two amino groups in compound 34 due to the 
delocalization of electron density from the nitrogens to the carbonyl oxygens compared to 
unconjugated amino groups might also contribute to this lack of reactivity. No previous 





















2.5 Synthesis of 4-amino-3-[((1R, 3S)-3-hydroxymethyl-4-cyclopen 
tene)-1-amino]-3-cyclobutene-1,2-dione (27) 
Our synthesis of compound 27 started from commercially available (1R)-(-)-2-
azabicyclo[2.2.1]hept-5-en-3-one 41.  The synthesis of this compound 41 is shown in 
Figure 10 [59, 60].  It starts from cyclopentadiene and arylsulfonyl cyanide.  They react 
at room temperature for 30 min to generate 3-benzyl-2-azabicyclo[2.2.2]hepta-2,5-diene, 
which is hydrolyzed with acetic acid and water to (+/-)-lactam ((+/-)-2-
azabicyclo[2.2.2]hept-5-en-3-one) [59].  Then enantiospecific and enantiocomplementary 
hydrolyase of (+/-)-lactam are catalysed by whole cell preparations of microbial strains 
ENZA-1 (Rhodococcus equi) and ENZA-20 (Pseudomonas solanacearum) [60].  From 
the fermentation using the ENZA-1, (+)-lactam is obtained.  From an equally facile 
bioconversion ENZA-20 produces (-)-lactam (compound 41, > 98% optical purity) [60].  
The racemate and each of the enantiomers ( ≥ 98% purity with ≥ 99% (HPLC) optical 
























(+)-4-amino-2-cyclopentenyl-1-carboxylic acid  
Figure 10: Reaction scheme for synthesis of starting material (1R)-(-)-2-azabicyclo 
[2.2.1]hept-5-en-3-one 41 [59, 60] 
 
There are several established routes to give cyclopentenylamine from the bicyclic 
lactam 41  [61-63].  We made the pure amine alcohol 44 from lactam 41 in three, high-
yielding steps (Scheme 2.8) based on the method reported by Taylor et al. [63].  To 
cleave the amido bond, the tert-butoxycarbonyl (Boc) group was introduced to the 2-
position of 41 by the reaction of lactam 41 with di-tert-butyldicarbonate (Boc2O) in the 
presence of catalytic 4,4-dimethylaminopyridine (DMAP).  The resulting compound 42 
(71% yield) was then treated with sodium borohydride to give the N-Boc protected 
cyclopentene derivative 43 in 61% yield from 41.  The Boc amino alcohol 43 is a stable 
solid from which the pure amino alcohol 44 was generated under mild conditions using a 




































Transformation of 44 to 27 was carried out by a usual manner as shown in Scheme 2.8.  
As mentioned above, the second methoxyl group of squarate is active towards amines in 
basic condition.  So addition of N,N-diisopropylethylamine (pH > 8) as a base to a 
solution of the cyclopentenylamine 44 and 4-amino-3-methoxy-3-cyclobutene-1,2-dione 
33 in methanol should produce 27.  However, we could not obtain compound 27 under 
these conditions.   Most of the cyclopentenylamine 44 was found to be unreactive under 
these conditions.  So we were aware that the N,N-diisopropylethylamine was not strong 
enough to readily remove the trifluoroacetic group on 44 under the above preliminary 
experimental conditions. 
Another stronger base was needed for the reaction.  So a quantitative amount of 
sodium methoxide with 44 was added to the TFA salt 44 in order to completely remove 
the trifluoroacetate group and N,N-diisopropylethylamine was also added to adjust the 





















The structure of compound 27 is very novel.  So we tried to crystallize compound 27 
for X-ray to investigate the structure of this compound.  It was crystallized from 
methanol or ethanol for 1 week.  But it was disappointing that we could not achieve the 
crystal of compound 27 under these conditions. 
 
2.6 Synthesis of 4-methoxy-3-[((1R, 3S)-3-hydroxymethyl-4-cyclopen 
tene)-1-amine]-3-cyclobutene-1,2-dione (28) 
We combined the cyclopentene ring as the sugar part and the monoester monoamino 
squarate as the base to make the squarate monoester nucleoside analogue.  We also 
started from the commercially available (1R)-(-)-2-azabicyclo[2.2.1]hept-5-en-3-one 41 
to give the pure amino alcohol 44 under conditions similar to those previously presented 
(Scheme 2.10).  In order to avoid both methoxy groups reacting with the 
cyclopentenylamine 44, the pH of the mixture was controlled at around 7.0.  Under these 
conditions using microwave irradiation at 100 ºC for 60 min, compound 28 was 
generated in a yield of 67% based on starting compound 44.  Microwave irradiation was 
applied using a Biotage Initiator 8 instrument.  The advantages of microwave irradiation 
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include not only improving classical reactions, shortening reaction times, improving 
yields, and suppressing byproduct formation as compared with conventional thermal 



































2.7 Synthesis of 4-hydroxy-3-[((1R, 3S)-3-hydroxymethyl-4-cyclopen 
tene)-1-amine]-3-cyclobutene-1,2-dionate, sodium salt (29) 
The first four steps of the synthesis of this compound are the same as presented in 
Scheme 2.10.  Treatment of compound 28 with 0.1 M sodium hydroxide (1 equivalent) 
under ice-cooling for 3 hours and then at room temperature for 7 hours  under argon gave 


















2.8 Synthesis of (1R, 2S, 3R, 5R)-4-amino-3-[(5-hydroxymethyl-cyclo 
   pentane-1,2-diol)-3-amino]-3-cyclobutene-1,2-dione (30) 
The starting material (1R)-(-)-2-azabicyclo[2.2.1]hept-5-en-3-one 41 was subjected to 
cis-dihydroxylation utilizing catalytic quantities of osmium tetroxide, in the presence of 
N-methylmorpholine N-oxide (NMO) to regenerate the OsO4 (acetone/H2O, room 
temperature) [69].  The glycolization product 45, obtained in 95% yield, was protected by 
its addition to a stirred solution of p-toluenesulphonic acid (TsOH) monohydrate in 2,2-
dimethoxypropane (2,2-DMP) and dimethylformamide (DMF) at room temperature for 
20 hours.  This was then followed by the addition of acetonitrile, N, N-4-
dimethylaminopyridine (DMAP) and di-tert-butyl dicarbonate (Boc2O) to the solution.  
The solution was stirred at room temperature for 15 hours in attempts to prepare the 
protected compound 46 (Scheme 2.12) [70]. 
It was disappointing that we did not get the protected compound 46.  The spots on the 
TLC were numerous and the TLC was itself very complex.  We tried 1:10:1, 1:10:1.2, 
1:1:1.2 ratio of compound 45, 2, 2-DMP, and TsOH.  The spots on the TLC were the 
same and still complicated.  Also, the amount of added catalyst would affect the reaction 
no matter it is too much or not enough.  We tried 1:2 amount of catalytic DMAP with 
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Boc2O which was the same as that for preparing the N-Boc protected cyclopentene 
derivative 43.  The DMAP might be too much for this reaction.  We will continue to try 
different ratios to find the best conditions for this reaction and then finish the following 


























































2.9 Experimental procedures 
2.9.1 General experimental 
    Reagent grade solvents were used throughout the course of this work.  Reagents were 
purchased commercially from Chemstore, at University of Waterloo and used without 
further purification.  MeOH was HPLC grade. 
    Solvent evaporation was carried out under reduced pressure using a Buchi rotary 
evaporator with a Wheaton water aspirator).  Aqueous solutions were dried in vacuo by a 
rotary evaporator with a vacuum pump or on a lyophilizer under reduced pressure. 
    For thin layer chromatography (TLC) analysis, Merck silica gel 60 F254 aluminum 
sheets were used.  The developed sheets were viewed under UV light or stained with 
iodine, ninhydrin, vanillin, phosphomolybdic acid stain or potassium permanganate [71].  
At an early stage, flash chromatography was performed using silica gel 60 (70-230 mesh).  
At the later stage, flash chromatography was carried out using the Discovery-Scale 
FLASHTM Chromatography Systems and Modules (Biotage, USA) and using the FLASH 
Purification Cartridges (Biotage, USA) instead of using the silica gel packed by myself.  
The latter FLASH chromatography systems allowed for faster flow rates and provided 
increased throughput and higher resolution. The solvent mixtures used as eluent are 
indicated in each case.  Moreover, the experimental reactions were performed using the 
InitiatorTM Microwave Synthesis System Initiator 8 (Biotage, USA) at the later stage, 
which is able to quickly achieve temperatures and pressures beyond traditional reflux 
heating. 
    Proton (1H) and carbon (13C) proton decoupled nuclear magnetic resonance (NMR) 
spectra were obtained on Bruker AM-300 and AM-500 instruments.  Chemical shifts (δ) 
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for 1H NMR spectra run in CDCl3, DMSO-d6, CD3OD, D2O are reported in ppm relative 
to the internal standard tetramethylsilane (TMS) (δ = 0).  For 13C NMR spectra, chemical 
shifts are reported in ppm relative to CDCl3 (δ = 77.0 for central peak), DMSO-d6 (δ = 
39.5 for central peak), CD3OD (δ = 49.5 for central peak) and D2O (δ = 0 for external 
standard TMS) [72].  Coupling signals were assigned based on correlation spectroscopy 
(COSY) and heteronuclear multiple quantum correlation (HMQC) data.  Mass spectra 
were obtained at the WATSPEC Mass Spectrometry Facility, Department of Chemistry, 
University of Waterloo.  Low-resolution (LRMS) and high-resolution (HRMS) electron 
impact (EI) mass spectra were recorded on a JEOL HX 110 double focusing mass 
spectrometer. Electrospray Ionization (ESI) mass spectra were obtained with a 
Waters/Micromass QTOF Ultima Global mass spectrometer.  Melting points were 
measured on a Mel-Temp Melting Point Apparatus and are uncorrected.  Fourier 
transform infrared spectra were recorded on a Perkin-Elmer 1600 FT-IR using solid 












The following chemicals were purchased from the Sigma-Aldrich Company, Canada: 
(1R)-(-)-2-azabicyclo[2.2.1]hept-5-en-3-one, N,N-diisopropylethylamine, triethylamine, 
di-tert-butyldicarbonate, dimethylformamide, 3,4-dihydroxy-3-cyclobutene-1,2-dione, 
4-dimethylaminopyridine, sodium borohydride, 2,2-dimethoxypropane, sodium 
methoxide, 4-methylmorpholine N-oxide, trimethyl orthoformate, osmium tetroxide, and 
2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate salt.  
Deuterated solvents were purchased from Cambridge Isotope Laboratories, USA.  
The following were purchased from EMD Chemical Inc., USA: anhydrous diethyl ether, 
acetone, and N, N-dimethylformamide. 
    The following chemicals were purchased from Fisher Scientific, Canada: acetic acid, 
magnesium sulfate, hydrochloric acid, Celite 545®. 
    The following chemicals were purchased from Caledon Laboratories LTD, Canada: 
trifluoroacetic acid, sodium hydroxide. 
    The following chemical was purchased from J. T. Baker Chemical Co., USA: p-






































































9-methyladenine 1-methylcytidine 1-methyluracil9-methylguanine  
 
Molecular modeling was carried out by using Spartan 06, version 1.0.3 for Mac 
(Wavefunction Inc., Irvine California) molecular modeling software. Molecules were 
drawn using the graphical user interface.  The above molecules were used in calculations 
as simpler analogs of the intact nucleosides which would have required the presence of 
the ribose ring: 9-methyladenine, 1-methylcytidine (4-amino-2-hydroxy-1-
methylpyrimidine), 9-methylguanine, 1-methyluracil and N-methyl-diaminosquaramide. 
These compounds were then geometry optimized at the RHF/3-21G* level. The resulting 
structures were then superimposed such that the three CH3-N-C heavy atoms of N-
methyl-diaminosquaramide were overlapped (using the “superimpose” command in 
Spartan) with the CH3-N9-C4 of 9-methyladenine, the CH3-N1-C2 of 1-methylcytidine, 
 43
the CH3-N9-C4 of 9-methylguanine (showing two orientations of the squaramide), and 













To a 50 ml round-bottomed flask was added 3,4-dihydroxy-3-cyclobutene-1,2-dione 
(squaric acid, 2.053 g, 18 mmol), methanol (18 ml), and trimethyl orthoformate (4 ml, 
36.5 mmol).  The reaction mixture was refluxed at 56 °C for 24 hours.  The crude product 
was then concentrated under reduced pressure.  The pale yellow solid was dissolved in 
methylene chloride and purified on a silica gel column (EtOAc: Hexanes 1:2) to give 
dimethyl squarate (2.29 g, 89.4%) as a white solid. 
 
mp 55-57 °C (lit. 56-58 °C) [55];  
1H NMR (300 MHz, CD2Cl2) δ 4.34 (6H, s, OCH3)  
13C NMR (75 MHz, CD3OD) δ 189.35 (C2, C=O), 189.35 (C1, C=O), 184.35 (C3), 
184.35 (C4), 60.29 (OCH3), 60.29 (OCH3) 














Dimethyl squarate 32 (0.903 g, 6 mmol) was dissolved in 150 ml of dry diethyl ether 
under ice-cooling and was added ammonia gas until precipitation was completed (~ 30 
mins).  The mixture was boiled gently for 10 mins and the ether was decanted.  The 
residue was then washed with ether, dried in vacuo, and crystallized from acetone-
petroleum ether (1:1) to give the product (0.617g, 81%) as a pale yellow solid. 
 
mp 200-202 °C (lit. ~202 °C) [55]; 
1H NMR (300 MHz, acetone-d6) δ 4.31 (3H, s, OCH3), 7.39 (2H, brs, NH2);   
13C NMR (75 MHz, DMSO- d6) δ 190.25 (C2, C=O), 183.63 (C1, C=O), 178.50 (C3), 
174.27 (C4), 60.17 (OCH3).  The 13C NMR spectrum recorded was in complete 
agreement with the theoretical prediction (δ190.41 (C2, C=O), 185.06 (C1, C=O), 179.50 
(C3), 175.25 (C4), 60.34 (OCH3)) 
















Dimethyl squarate 32 (0.142 g, 1 mmol) was dissolved in 25 ml of dry methanol under 
ice-cooling and was added ammonia gas until precipitation was completed (~ 20 mins).  
The mixture was warmed for 1h, the methanol was decanted.  The residue was washed 
with acetone and ether, and then dried in vacuo to give the product (0.092 g, 82%) as a 
yellow powder. 
 
It does not melt, turning dark over 248 °C, no visible gas evolution when heated to 380 
°C (lit. no noticeable gas evolution when heated to 350 °C) [55]; 
13C NMR (75 MHz, DMSO- d6) δ 184.22 (C2, C=O), 184.22 (C1, C=O), 170.74 (C3), 
170.74 (C4) 




















To a solution of 2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate salt 
(0.036 g, 0.1 mmol) (commercially available from Sigma-Aldrich Company) in 4 ml 
methanol, the squarate 33 (0.013 g, 0.1 mmol) was added and  N,N-
diisopropylethylamine (1.1 ml) was added to adjust the pH of the mixture to 8 ~ 9.  The 
mixture was stirred at 68 °C-70 °C for 2 days, or 3 days, or 7 days and then condensed 
under in vacuo, giving a brownish-yellow residue. 
 
Methanol was substituted by 1, 4-dioxane.  The other conditions were the same as above. 
 
To a solution of 2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate salt 
(0.108 g, 0.3 mmol) (commercially available from Sigma-Aldrich Company) in 5 ml 
methanol, the squarate 33 (0.038 g, 0.3 mmol) was added and sodium methoxide (0.016 g, 
0.3 mmol) was added.  The mixture was stirred at 68 °C-70 °C for 2 days, or 3 days, or 7 
days and then condensed under in vacuo, giving an orange residue.  The residue from 7-
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day reaction was purified on a silica column (EtOAc: methanol = 50:1) to give an orange 
solid. 
 
LRMS FAB: m/z Calcd. For C12H16O6N2 (M + H+): 285.1086. Found 285.1048.  
However, the purified product was found to be a mixture based on observation of the 
TLC and mass spectrum.  There are three spots on TLC and these three spots had similar 
Rf values.  Extensive attempts were made to purify these but these attempts were not 
successful.  Therefore it was used directly for the next reaction. 
 
To a solution of 2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate salt 
(0.108 g, 0.3 mmol) (commercially available from Sigma-Aldrich Company) in 7 ml 
methanol, the squarate 33 (0.038 g, 0.3 mmol) was added and sodium methoxide (0.016 g, 
0.3 mmol) was added.  The mixture was stirred at 68 °C-70 °C for 1 hour.  More sodium 
methoxide (0.016 g, 0.3 mmol) was added and the mixture was stirred at 68 °C-70 °C for 
2 days, or 7 days and then condensed under in vacuo, giving an orange residue. 
 
In all cases, the TLC results were extremely complex and numerous compounds were 
present. But mass spectrometric analysis of the residue from each reaction was in 


















To triethyl orthoformate (1 ml) was added the impure compound 39 (22 mg, 0.08 mmol) 
and half drop of conc. hydrochloric acid.  The mixture was stirred in a sealed flask at 
room temperature for 1 day and then concentrated to give an oil that was further purified 
by column chromatography (CHCl3: CH3OH = 99:1) to give the products.  Mass 















To triethyl orthoformate (4 ml) was added the diamino squarate 34 (0.112 g, 1 mmol) and 
2 drops of conc. hydrochloric acid.  The mixture was stirred in a sealed flask at room 
temperature for 1 day.  Most of the yellow diamino squarate powder was still left in the 
solution. 
 
The same amount of reagents and reactant was performed for this reaction.  The mixture 
was run under microwave conditions for 1 h at 100 °C.  After the reaction, the mixture 
















(1R)-(-)-2-Azabicyclo[2.2.1]-hept-5-en-3-one (0.546 g, 5 mmol) (commercial from 
Sigma-Aldrich Company, ≥ 98% purity with ≥ 99% (HPLC) optical purity) was 
dissolved in CH2Cl2 (10 ml).  To this solution were added successively triethylamine (0.7 
ml, 5 mmol), di-tert-butyl dicarbonate (2.183 g, 10 mmol), and 4-dimethylaminopyridine 
(0.611 g, 5 mmol). The mixture was stirred for 24 hours at room temperature.  The 
solvent was removed in vacuo. To the resulting residue was added water (5 ml) and ether 
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(5 ml).  The organic layer was collected, dried (anhydrous MgSO4) and concentrated in 
vacuo.  The residue was purified by column chromatography (hexane: EtOAc = 5:1) to 
give the product (0.740 g, 71%) as colorless prisms. 
 
mp 85-86 °C (lit. 84-86 °C) [63] 
1H NMR (300 MHz, CDCl3) δ 1.48 (9H, s, Boc, C(CH3) 3), 2.14 and 2.34 (each 1H, AB 
type, C7-H2), 3.36 (1H, br s, C4-H), 4.93 (1H, m, C1-H), 6.65 (1H, dm, C5-H), 6.88 (1H, 
dd, J = 5.3 Hz, 2.2 Hz, C6-H).  The 1H NMR spectrum recorded was in complete 
agreement with the data reported in the literature [73]. 
 
 










The product 42 (2.220 g, 10.6 mmol) from the previous reaction was dissolved in 
methanol (21 ml).  NaBH4 (1.203 g, 31.8 mmol) was added with stirring under ice 
cooling.  Stirring was continued for 30 mins at 0 ºC, and then stirred at room temperature 
for 1 h.   The mixture was neutralized with 10% HCl in H2O and then concentrated in 
vacuo.  The residue was purified by silica gel chromatography (50% EtOAc/hexane) to 
give 1.95 g (86.4%) of colorless prisms. 
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mp 58-62 °C (lit. 56-60 °C) [73] 
1H NMR (300 MHz, CD3OD) δ 1.23 (1H, m, C5-H), 1.41 (9H, s, Boc, C(CH3) 3), 2.41 
(1H, m, C5-H), 2.74 (1H, s, C1-H), 3.46 and 3.48 (2H, d, J = 6.0, CH2OH), 4.55 (1H, s, 
C4-H), 5.67 (1H, s, C3-H), 5.80 (1H, s, C2-H).  The 1H NMR spectrum recorded was in 
complete agreement with the data reported in the literature [63]. 
13C NMR (75 MHz, MD3OD) δ 156.35 (BOC, C = O), 142.33 (BOC, C), 134.05 (C3), 
132.50 (C2), 78.53 (CH2OH), 64.94 (C4), 55.96 (C5), 34.20 (C1), 27.28 (BOC, CH3) 
LRMS FAB: m/z Calcd. For C11H19NO3 (M + H+) 214.1443. Found 214.1391 
 
 











To trifluoroacetic acid (TFA) (2 ml) was added 43 (426 mg, 2 mmol) under ice-cooling. 
The mixture was stirred at room temperature for 2 h, and then evaporated in vacuo to 
give a brown oil (428.80 mg, 94%).  The residue was used directly for the next reactions 




















4' 5'  
 
To a solution of 44 (428.8 mg, 1.88 mmol) in methanol (4 ml), squarate 33 (238.8 mg, 
1.88 mmol) and sodium methoxide (101.5 mg, 1.88 mmol) were added. The pH of the 
mixture was adjusted to 9.0 ~ 10 by N, N-diisopropylethylamine (1.2 ml). Then the 
mixture was run under microwave conditions for 1 h at 100 °C. After the reaction, 
precipitation occurred and was filtered to obtain the crude product (233.0 mg). The 
crude product was recrystallized from methanol to provide the product (192.3 mg, 49%) 
as orange powder. 
 
The orange powder (15 mg) was dissolved in boiled methanol or ethanol to make the 
supersaturated solution, which was then quickly filtrated while it was hot.  The filtrated 
solution was cooled down to room temperature and then was crystallized at room 




mp 278 °C 
1H NMR (300 MHz, DMSO-d6) δ 1.28-1.36 (1H, m, C2’-H), 2.33-2.43 (1H, m, C2’-H), 
2.67-2.69 (1H, m, C3’-H), 3.28 and 3.36 (2H, d, CH2OH), 4.67 (1H, s, C1’-H), 5.02 (1H, 
brs, OH ) 5.72-5.74 (1H, d, J = 6.0, C4’-H), 5.88-5.90 (1H, d, J = 6.0, C5’-H), 7.40 (2H, 
brs, NH2) 
13C NMR (75 MHz, DMSO-d6) δ 183.62 (C2, C=O), 183.24 (C1, C=O), 169.58 (C3), 
167.97(C4), 136.73 (C5’), 132.55 (C4’), 64.83 (CH2OH), 59.60 (C1’), 47.76 (C3’), 35.57 
(C2’) 
Here are the predicted 13C NMR values using the ACD/Labs' 13C and 1H NMR prediction 
software: δ 193.4 (C2, C=O), 193.4 (C1, C=O), 152.0 (C3), 144.5 (C4), 136.5 (C5’), 
136.5 (C4’), 67.5 (CH2OH), 64.5 (C1’), 42.0 (C3’), 38.3 (C2’). But here is the literature 
[74] and it is in agreement with this literature. 
LRMS (EI): 208.13(100), 177.10 (10), 150.08 (36), 133.10 (8), 112.04 (13), 94.08 (16), 
79.04 (57), 56.32 (50) 
HRMS FAB: m/z Calcd. For C10H12N2O3 (M + H+) 209.0926. Found 209.0926 
IR (KBr) 3500-3000 cm-1 (OH), 3295.8, 3169.0 cm-1 (NH2), 2939.6 cm-1 (C-H), 1806.1 
cm-1 (C=O), 1642.4 cm-1 (C=O), 1569.5 cm-1 (C=C), 1518.7 cm-1 (C=O), 1478.1 cm-1 (C-














































































































































































































































































































































































4' 5'  
 
To a solution of 44 (638.6 mg, 2.8 mmol) in methanol (5 ml), dimethyl squarate 32 (398 
mg, 2.8 mmol) and sodium methoxide (151.2 mg, 2.8 mmol) were added. The pH of the 
mixture was adjusted to 7.0 by N, N-diisopropylethylamine (1 ml). The reaction was run 
under microwave conditions for 60 mins at 100 °C. Then the mixture was concentrated 
in vacuo. The residue was purified on a silica column (CHCl3: CH3OH = 95:5) to give 
the product (421.5 mg, 67%) as pale yellow oil. 
 
1H NMR (300 MHz, CDCl3) δ 1.36-1.40 (1H, m, C2’-H), 2.29-2.39 (1H, m, C2’-H), 2.68 
(1H, m, C3’-H), 3.30-3.34 (2H, m, CH2OH), 4.24-4.27 (3H, d, J = 9.0, OCH3 ), 4.63-
4.66 (1H, m, C1’-H), 5.07 (1H, brs, OH ) 5.69 (1H, s, C4’-H), 5.88-5.89 (1H, m, C5’-H) 
13C NMR (75 MHz, DMSO-d6) δ 189.51 (C1, C=O), 182.46 (C2, C=O), 177.51 (C3), 
171.36(C4), 136.63 (C5’), 131.77 (C4’), 64.90 (CH2OH), 60.22 (C1’), 59.93 (OCH3), 
47.85 (C3’), 35.05 (C2’).  The 13C NMR spectrum recorded was compared to literature 
[74].  It compares favorably. 
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LRMS (EI): 223.10 (100), 192.08 (24), 165.05 (50), 149.06 (7), 134.06 (20), 128.04 (8), 
97.07 (11), 79.02 (65), 67.07 (36), 66.07 (19) 

























































































































































































































































































































































































Figure 16: Mass spectrum (EI+) for compound 28 
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3-Hydroxy-4-[((1R,3S)-3-hydroxymethyl-4-cyclopentene)-1-amino]-3-cyclobutene-













4' 5'  
 
The product 28 (223 mg, 1 mmol) from the previous reaction was dissolved in cooled 
methanol (10 ml). To this solution was added dropwise cooled 0.1 M sodium hydroxide 
(10 ml). The mixture was stirred at 4 °C for 3 hours and then stirred at room 
temperature for another 7 hours. After removal of the solvent in vacuo, the residue was 
subjected to flash chromatography (CHCl3: CH3OH = 10: 1), giving the product (185.4 
mg, 80%) as yellow powder. 
 
mp 160 °C 
1H NMR (300 MHz, DMSO-d6) δ 1.30-1.33 (1H, m, C2’-H), 2.31-2.33 (1H, m, C2’-H), 
2.67 (1H, m, C3’-H), 3.36 and 3.38 (2H, d, CH2OH), 4.66-4.68 (1H, m, C1’-H), 5.11-
5.12 (1H, brs, OH ) 5.69-5.70 (1H, m, C4’-H), 5.78-5.79 (1H, m, C5’-H), 6.72-6.74 (1H, 
brs, NH) 
13C NMR (75 MHz, DMSO-d6) δ 199.56 (C1, C=O), 199.56 (C2, C=O), 188.88 (C4), 
181.31 (C3), 134.75 (C5’), 134.26 (C4’), 65.08 (CH2OH), 58.77 (C1’), 47.75 (C3’), 35.74 
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(C2’).  These 13C NMR values are in agreement with those for the similar compounds 
from the literature [75]. 
LRMS FAB: m/z Calcd. For C10H10NO4 + Na+ (M + H+) 232.0586. Found 232.0509 

































































































































































































































































































































































To a solution of (1R)-(-)-2-azabicyclo[2.2.1]hept-5-en-3-one (0.546 g, 5 mmol) 
(commercial from Sigma-Aldrich Company, ≥ 98% purity with ≥ 99% (HPLC) optical 
purity) and N-methylmorpholine N-oxide (1.375 g, 10 mmol) in acetone/water (8:1, 100 
ml),  osmium tetroxide (65 mg, 0.05 mmol) was added and the mixture was stirred for 4 h. 
The mixture was diluted with acetone (75 ml) and an excess of solid sodium hydrogen 
sulfite was added in order to destroy the oxidant. The suspension was filtered through 
Celite and the Celite was washed with an additional 25 ml of acetone. The filtrate was 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (CHCl3: CH3OH = 10:1) to give a white solid (679.5 mg, 95%). 
 
1H NMR (300 MHz, D2O) δ 1.92 (2H, s, C5-H, C6-H), 2.47 (1H, s, C4-H), 3.63 (1H, s, 
C1-H), 3.85-3.92 (2H, dd, J = 13.9 Hz, 5.9 Hz, C7-H2).  
LRMS (EI): 143.13 (22), 125.12 (8), 114.12 (2.5), 96.11 (7), 81.06 (5), 83.6 (100), 55.40 













The product 45 (143.1 mg, 1 mmol), 2,2-dimethoxypropane (1.1 ml, 10 mmol), p-
toluenesulphonic acid (190.2 mg, 1 mmol) were dissolved in dimethylformamide (4 ml).  
The mixture was stirred at room temperature for 20 hours and then concentrated in vacuo.  
Without further purification, the residue was dissolved in acetonitrile (4 ml).  To this 
solution were added di-tert-butyl dicarbonate (436.5 mg, 2 mmol) and 4-
dimethylaminopyridine (122.2 mg, 1 mmol).  The solution was stirred at room 
temperature for 15 hours and then concentrated in vacuo, furnishing the dark residue. 
 
The ratio of compound 45, 2,2-DMP, TsOH was changed to 1:10:1.2 or 1:1:1.2.  The 












3.1 Anticancer activity studies 
3.1.1 Human tumour cell line screen 
The three compounds 27, 28, 29 were sent to the Developmental Therapeutics Program 
(DTP) of the National Cancer Institute (NCI, USA) to have a complete screen of their 
anticancer activity.  Compound screening at DTP has focused on the response of a panel 
of 60 human tumour cell lines [76], representing nine distinct tumour types: leukemia, 
colon, lung, central nervous system (CNS), renal, melanoma, ovarian, breast and prostate.  
The NCI 60 human tumour cell line anticancer drug screen (NCI60) was developed in the 
late 1980s as an in vitro drug-discovery tool with a rich source of information about the 
mechanisms of growth inhibition and tumour-cell kill [77]. The three synthetic 
compounds were analyzed for selective growth inhibition or cell killing of particular 
tumour cell lines.  The screening begins with the evaluation of all compounds against the 
60 cell lines at a single dose of 10 μM.  The output from the single dose screen is a 
biological response pattern and is reported as a mean graph, which is available for 
analysis in pattern recognition algorithms (COMPARE program) [78].  Using these 
algorithms, it is possible to assign a putative mechanism of action to a test compound, or 
to determine that the response pattern is unique and not similar to that of any of the 
standard prototype compounds included in the NCI database.  In addition, following 
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characterization of various cellular molecular targets in the 60 cell lines, it may be 
possible to select compounds most likely to interact with a specific molecular target. 
After the analysis by the COMPARE program, compounds which exhibit significant 
growth inhibition might be evaluated against the 60 cell panel at five concentration levels. 
 
3.1.1.1 Results and discussions 
The NCI60 screening data for compounds 27, 28, 29 against 60 different human 
tumour cell lines are presented in Figures 20, 21, 22 respectively.  By convention, bars to 
the left indicate resistance, and bars to the right indicate sensitivity.  As shown in Figure 
20, non-small cell lung cancer (EKVX), colon cancer, breast cancer, renal cancer 
(ACHN), melanoma (SK-MEL-28), and CNS cancer cells were relatively unaffected by 
compound 27.  But non-small cell lung cancer (A549/ATCC, HOP-62 and NCI-H522), 
ovarian cancer, leukemia, renal cancer (UO-31) and melanoma exhibit some sensitivity to 
compound 27 at the 10 micromolar level (Figure 20).  Among these somewhat sensitive 
cell lines, renal cancer (UO-31) cell line expresses the highest growth inhibition (22%) by 
compound 27. The others are inhibited by 9% ~ 18%.  
The profiles of cell line responses for compound 28 are similar to those for compound 
27. Compound 28, at the 10 micromolar level, appears to have moderate growth 
inhibition on non-small cell lung cancer (NCI-H522), colon cancer (KM12), renal cancer 
(UO-31), and melanoma (UACC-257) cells, whose growth inhibition rates are 18%, 17%, 
16% and 16% respectively (Figure 21). 
Compound 29, at the 10 micromolar level, appears to have moderate growth inhibition 
against CNS cancer (SF-295) cells, which was inhibited up to 36% of growth. Non-small 
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cell lung cancer (NCI-H522) showed 20% growth inhibition. Several other cell lines 
exhibited growth inhibition ranging from 1% to 12% (Figure 21). 
As a result, several of the 60 human tumour cell lines could be inhibited to some extent 
at a single dose of 10 μM of compounds 27, 28, 29. However, they did not exhibit 
significant growth inhibition and no further testing is recommended by the National 











































3.1.2 Cell viability and proliferation 
  We were interested in undertaking some preliminary tumour cell viability studies in the 
presence of our three nucleoside analogues while waiting for anticancer testing by the 
NCI.  In vitro and living cell measurements of cell death were conducted in Dr. Qing-Bin 
Lu’s laboratory at the University of Waterloo.  The colorimetric assay kits were used for 
the analysis of cell viability.  Vybrant® MTT cell proliferation assay kit is a non-
hazardous, precise, rapid, colorimetric, straightforward and lack of any radioisotope assay 
for monitoring cell viability [79].  So Vybrant® MTT cell proliferation assay kit (V-
13154) was used to monitor the growth rate of a cell population and the amount of live 
cells.  Unlike other colorimetric assays, the MTT assay can be used with all cell types.  It 
is based on the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), which measures only living cells and the results can be 
read on standard microplate absorbance readers at 570 nm [80].  This colorimetric assay 
involves the conversion of the yellow tetrazolium salt MTT to the blue formazan 
derivative by mitochondrial enzymes in viable cells.  It is a sensitive assay with excellent 
linearity up to approximately 106 cells per well. 
 
3.1.2.1 Materials and methods 
3.1.2.1.1 Reagents 
Eagle’s minimum essential medium with phenol red, Eagle’s minimum essential 
medium without phenol red, MEM non-essential amino acid solution (100x), Dulbecco’s 
phosphate buffered saline (PBS), and L-glutamine were purchased from the Sigma-
Aldrich Company, Canada.  Vybrant® MTT cell proliferation assay kit (including MTT 
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and sodium dodecyl sulfate (SDS)) and penicillin-streptomycin were purchased from 
InvitrogenTM Corporation, USA.  Fetal bovine serum (FBS) was purchased from ATCC, 
USA.  Trypsin EDTA, 1x (0.25% trypsin/2.21 mM EDTA in Hank’s balanced salt 
solution (HBSS) without sodium bicarbonate, calcium & magnesium) was purchased 
from Mediatech, Inc., USA.  Reagent grade hydrochloric acid was purchased from Fisher 
Scientific Co., Canada. 
 
3.1.2.1.2 Growth of HeLa cell line 
HeLa (Human epithelial cervical adenocarcinoma cell line) cells were routinely grown 
in Eagle’s minimum essential medium with phenol red containing 1% of MEM non-
essential amino acid solution, 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin as antibiotics.  Cultures were maintained in BD falcon tissue culture flasks 
in a humidified atmosphere of 95% air/ 5% carbon dioxide at 37 ºC CO2 Incubator 
(Thermo Electron Corporation).  Cells were removed by trypsinization and subcultured 
according to the following procedure.  Medium was decanted, and the cells were rinsed 
once with 2 ml of sterile phosphate-buffered saline (PBS) (pH = 7.4).  The cells were 
then overlaid for 1-3 min with 0.5 ml of trypsin.  Cells were passaged at 85-90% of 
confluency in BD falcon tissue culture flasks.  All cell counts were performed on a 
Hemacytometer purchased from Bright-Line, USA.  Compound 27, 28, 29 were prepared 
in Eagle’s minimum essential medium with phenol red at the following concentrations: 




3.1.2.1.3 MTT assay 
After 85-90% of cell confluency, the cells were trypsinized as described above and 
seeded at a concentration of 2.5 x 104 cells/ml.  Cells (200 μl) were introduced into each 
well of 96-well culture plates.  After 24 hours incubation, the old medium was removed 
and different concentrations of compound 27, 28, 29 were added in triplicate. The plate 
was incubated at 37 ºC for 24 hours.  Then the medium containing the compounds were 
removed.  Eagle’s minimum essential medium (100 μl) without phenol red containing 0.1 
% of 200 mM L-glutamine and 10 μl of 12 mM MTT in sterile PBS were added to each 
well.  After an incubation time of 4 hours, SDS-HCl (100μl , 1 gm SDS/ 10 ml of 0.01 M 
HCl) was added to each well and the plate was incubated for another 12 hours.  
Absorption of each well was assayed by a scanning multiwell spectrophotometer at 570 
nm (Thermo Labsystems, Canada). 
 
3.1.2.2 Results and discussions 
As shown in Figure 23, HeLa cells were unaffected by compounds 28, 29 at 100, 200, 
300, 400, and 500 μM but was sensitive to compound 27 at 300 μM.  Cisplatin is a 
chemotherapy drug for the treatment of various types of cancers.  For comparison, almost 
all HeLa cells are dead by cisplatin at 50 μM (Figure 24).  The concentrations we tested 
were much higher than 50 μM.  Since there was no significant effect on the HeLa cell by 
compounds 27, 28, 29, no further experiments at lower concentrations were followed. 
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Figure 23: MTT data for compounds 27, 28, 29 at 100, 200, 300, 400, and 500 μM 
 74
 











0 10 20 30 40 50













Figure 24: MTT data for Cisplatin at 10, 20, 30, 40, and 50 μM 
 
3.2 Antiviral activity studies 
The National Institute of Allergy and Infectious Diseases (NIAID) has established the 
Antimicrobial Acquisition and Coordinating Facility (AACF) to provide free and 
confidential services for submitting compounds to be evaluated for antiviral activity.  The 
AACF uses animal models for evaluating antiviral agents against the following viruses:  
SARS, Respiratory panel (Flu A, Flu B, RSVS, PIV, Measles, HRV, Adeno) and the 
Biodefense panel (Rift Valley Fever, Tacaribe, VEE, Yellow Fever, WNY, Dengue) [81], 
Pox panel (Cowpox, Vaccinia), Herpes panel (HSV-1, HSV-2, VZV, EBV, CMV), 
Hepatitis B virus, Hepatitis C virus [82], Human papilloma virus (HPV).  The three 
synthesized compounds 27, 28, 29 have been sent to AACF to screen their potential 
antiviral activity against all the above viruses.  This was determined after discussions 
with Dr. Tseng at NIAID.  Confidentiality agreements were signed between the 
University of Waterloo and NIAID to ensure structure confidentiality in the event that the 
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patenting of the compounds would be of interest. Compounds demonstrating reasonable 





























The objectives of this project were to explore the application of squaric acid analogues 
to the synthesis of novel nucleoside analogues and to examine their potential bioactivities.  
The syntheses of three nucleoside analogues containing the squaric acid moiety were 
completed. Their synthesis involved the reaction of (1R)-(-)-4-(hydroxymethyl)cyclopent 
-2-en-1-ylamine with either 4-amino-3-methoxy-3-cyclobutene-1,2-dione or react with 
3,4-dimethoxy-3-cyclobutene-1,2-dione, followed by hydrolysis.  These three compounds 
were sent to NCI to screen for their potential anticancer activities.  Little to modest 
antitumour activity was detected for these compounds.  In addition, a study of their 
cytotoxity to HeLa cells was performed as well.  However, no significant effect was 
observed by these compounds.  Furthermore, these three compounds are currently being 
tested for their potential antiviral activity against various viruses by NIAID. 
 
4.2 Future work 
 
We will continue our attempts to try and crystallize compounds 27, 28, 29 for X-ray to 
investigate the structure of these three novel compounds. 
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We will also try to generate compound 46 by changing the ratios of reagents.  Once the 
protected compound 46 is furnished, it may undergo the reductive cleavage of the lactam 
using sodium borohydride in methanol to give the protected alcohol 47. Removal of both 
isopropylidene and Boc protecting groups by refluxing in trifluoroacetic acid (TFA, 
CF3COOH) should give the free cyclopentylamine 48 [70].  The condition of the last step 
will be the same as that of making the compound 27.  And it is hoped that this approach 
will afford (1R, 2S, 3R, 5R)-4-amino-3-[(5-hydroxymethyl-cyclopentane-1,2-diol)-3-





















































Another nucleoside analogue 49 like compound 28 could be synthesized by treatment 
of 48 with squarate diester 32 using sodium methoxide and N,N-diisopropylethylamine 





















If compound 49 is successfully obtained, we will also attempt to conduct the reaction 



















   
Once achieving these three compounds, we will send them to NCI and NIAID to 
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